State of the art in the treatment of Hodgkin lymphoma.
Hodgkin lymphoma (HL) has become one of the most easily curable malignancies in                 oncology. More than 80% of patients can be cured with risk-adapted treatment that                 includes chemotherapy and radiotherapy. This progress is mainly due to the                 development of multi-agent chemotherapy and improved radiation techniques; however,                 severe, life-threatening treatment-related side effects occur, which include organ                 toxicity and secondary malignancies. Thus, the treatment approaches must be                 carefully balanced between optimal disease control and the risk of long-term                 sequelae. Although this article is meant to provide an overview of the current                 treatment approaches for patients with HL, in many instances conflicting results                 from various clinical trials are available, and a personal judgment is inevitable.                 Here, we focus on evidence from large clinical trials with solid conclusions.
First Department of Internal Medicine, University Hospital                     Cologne, Kerpener Straße 62, D-50924                 Cologne, Germany.
Peter
P
Borchmann
Dennis A
DA
Eichenauer
Andreas
A
Engert
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans
D000970:Antineoplastic Agents